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We have previously shown that a severely energy-restricted diet leads to greater loss of weight, fat, lean mass and
bone mineral density (BMD) at 12 months in postmenopausal women with obesity than a moderately energy-
restricted diet. We now aim to evaluate whether these effects are sustained longer term (ie, at 36 months).
101 postmenopausal women were randomized to either 12 months of moderate (25 to 35%) energy restriction
with a food-based diet (moderate intervention), or 4 months of severe (65 to 75%) energy restriction with a total
meal replacement diet followed by moderate energy restriction for 8 months (severe intervention). Body weight
and composition were measured at 0, 24 and 36 months. Participants in the severe intervention lost ~1.5 to 1.7
times as much weight, waist circumference, whole-body fat mass and visceral adipose tissue compared to those in
the moderate intervention, and were 2.6 times more likely (42% versus 16%) to have lost 10% or more of their
initial body weight at 36 months (P < 0.01 for all). However, those in the severe versus moderate intervention lost
~1.4 times as much whole-body lean mass (P < 0.01), albeit this was proportional to total weight lost and there
was no greater loss of handgrip strength, and they also lost ~2 times as much total hip BMD between 0 and 36
months (P < 0.05), with this bone loss occurring in the first 12 months. Thus, severe energy restriction is more
effective than moderate energy restriction for reducing weight and adiposity in postmenopausal women in the
long term (3 years), but attention to BMD loss in the first year is required.
Trial registration: Australian New Zealand Clinical Trials Registry Reference Number: 12612000651886,
anzctr.org.au.u (R.V. Seimon), amanda.salis@uwa.edu.au (A. Sainsbury).
May 2020; Accepted 13 May 2020
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Overweight and obesity are major contributors to morbidity and
mortality globally [1]. The greater the degree of excess weight, the
greater the risk of disease [2]. Encouragingly, loss of excess weight has
been shown to reduce the risk of disease in people with obesity, with
greater weight losses (eg, 10% compared to 5% of initial body weight)
producing greater reductions in disease risk [3, 4, 5]. Some health
guidelines from around the world therefore recommend a minimum
weight loss of 10% for people with obesity [6].
The most effective and accessible way for people with obesity to
achieve 10% weight loss is with severely energy-restricted diets [7],
where energy intake is restricted to less than 35% of energy requirements
[8]. These diets are often implemented by replacing all or almost all
meals and snacks with nutritionally replete meal replacement products
(eg, shakes and bars), in meal replacement diets. In the short-term (weeks
to months), severely energy-restricted meal replacement diets induce
significantly greater average weight losses than food-based diets
involving moderate energy restriction [9, 10, 11]. In the long-term
(months to years), and contrary to expectations, severely
energy-restricted diets do not result in faster weight regain than
moderately energy-restricted diets [7, 12], and in fact result in greater
average weight losses at 3 years following completion of the diet [11].
Besides greater short- and long-term weight loss, severely
energy-restricted meal replacement diets offer additional advantages
over moderately energy-restricted food-based diets: ease of use (eg, no
need to prepare meals [13], and appetite is reduced during the diet,
facilitating adherence [14]); and low cost (it is cheaper to purchase meal
replacement products than the national average expenditure on food [15,
16], and meal replacement diets are 3 times cheaper than food-based
diets in terms of dietetics support [7], while also being cheaper than
bariatric surgery or anti-obesity medications).
Despite the above-mentioned advantages of severely energy-
restricted meal replacement diets, there are concerns about potential
long-term effects, notably on body composition [17]. Some clinical
practice guidelines from around the world either recommend against the
use of severely energy-restricted meal replacement diets for the treat-
ment of obesity in general [18, 19], or recommend against their use in
older adults specifically [20]. Some support for these guidelines comes
from our randomised controlled clinical trial in postmenopausal women
with obesity, the TEMPO Diet Trial (Type of Energy Manipulation for
Promoting optimummetabolic health and body composition in Obesity).
We showed that while a severely energy-restricted meal replacement diet
led to approximately 2-fold greater losses of weight as well as
whole-body fat mass and abdominal adipose tissue volume (subcutane-
ous and visceral) compared to a moderately energy-restricted food-based
diet at 12 months, it also led to an approximately 1.5-fold greater loss of
whole-body lean mass (albeit this was proportional to the greater weight
loss and there was no loss of handgrip strength), and an approximately
2.5-fold greater loss of hip bone mineral density at 12 months [9]. While
severely energy-restricted meal replacement diets clearly have benefits
for cardiometabolic health [3], an outstanding question is what happens
to body composition in the long-term (years)? In this paper, we thus
report on body composition outcomes from our 2-year and 3-year
follow-up of the postmenopausal women with obesity who participated
in the TEMPO Diet Trial.
2. Methods
2.1. Study design and participants
The rationale, design, and methods of this trial, including details on
sample size calculation, recruitment, inclusion, randomization,
assessment, and intervention during the first year, have previously
been reported [9, 21]. Briefly, the TEMPO Diet Trial was a single
center, randomized clinical trial. Ethical approval was obtained from2the Sydney Local Health District, Royal Prince Alfred Hospital Human
Research Ethics Committee. It was conducted at the Charles Perkins
Centre Royal Prince Alfred Clinic on the University of Sydney campus
in Camperdown, New South Wales, Australia, with magnetic resonance
imaging (MRI) scans performed at I-Med Radiology (Camperdown).
Reporting in this article is aligned with the Consolidated Standards of
Reporting Trials (CONSORT) reporting guideline, and the full trial
protocol can be found in Supplement 1 of our previous publication [9].
Key inclusion criteria were postmenopausal women aged 45 to 65
years with body mass index (calculated as weight in kilograms divided by
height in meters squared) from 30 to 40 kg/m2, at least 5 years after
menopause, with less than 3 h of structured physical activity per week
(ie, sedentary) and living in the Sydney metropolitan area of New South
Wales, Australia. Participants with osteoporosis, diabetes mellitus, or
taking medication affecting body composition, were excluded. The full
inclusion and exclusion criteria and our rationale for these have been
detailed in our published protocol [21]. The trial was conducted in
accordance with the Declaration of Helsinki [22] and Good Clinical
Practice guidelines [23]. All participants provided written informed
consent prior to participation.
2.2. Procedures
The moderate intervention involved a moderate energy restriction of
25 to 35% relative to estimated energy expenditure for a total of 12
months (52 weeks). This was achieved using a food-based diet, with
recommendations based on the Australian Guide to Healthy Eating [24].
The severe intervention involved a severe energy restriction of 65 to 75%
relative to estimated energy expenditure for 4 months (16 weeks) or until
a body mass index of no lower than 20 kg/m2 was reached, whichever
came first. This was achieved using a total meal replacement diet (Kic-
Start meal replacement shakes and soups from Prima Health Solutions)
supplemented with a whey protein isolate (Beneprotein from Nestle
Healthcare Nutrition) to achieve the prescribed protein target (described
later). This was followed by moderate energy restriction (ie, as in the
moderate intervention) for the remaining period to 12 months (52
weeks). For both interventions, a protein intake of 1.0 g/kg of actual
body weight per day was prescribed, and physical activity was encour-
aged but not supervised. After 12 months, participants were given the
option of attending monthly group support meetings, each of 60 to 90
minutes in duration, facilitated on a rotating basis by different members
of the research team (R.V.S., S.M., C.H., A.A.G, and A.S.), sometimes in
association with a guest facilitator (F.Q.d.L., A.L.P., R.A.H., M.B.,
M.S.H.S., C.K.S., C.D.M., E.S., and V.M.S.). The development process and
rationale behind the dietary interventions for the TEMPO Diet Trial, as
well as full details of the dietary interventions, have been published
previously [8].
2.3. Outcomes
This article reports the 24- and 36-month body composition outcomes
for the TEMPODiet Trial. All body composition outcomes were measured
at 0, 24 and 36months following randomization. Height was measured at
0 and 36 months only. All data were collected with participants lightly
clothed (ie, in a close-fitting sports bra and leggings or, for MRI scans, in a
gown and underpants only), without shoes, and with all metal jewellery,
accessories, and electronic devices removed.
Dual-energy x-ray absorptiometry (DXA), using a Discovery W bone
densitometer (Hologic), was used to assess whole-body lean mass,
whole-body fat mass, and BMD of the total left hip and anterior poste-
rior lumbar spine (L1-L4) [25]. A hydraulic hand dynamometer (Jamar,
Model 5030J1; Patterson Medical) was used to assess handgrip strength
of the dominant and nondominant hands. For the 2 participants who
were ambidextrous, the right and left hand were designated the domi-
nant and nondominant hand, respectively. Waist and hip circumfer-
ences were measured to the nearest 0.1 cm using a narrow, flexible, and
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circumference was measured in the midaxillary line at the halfway
point between the bony landmarks of the lowest rib and the top of the
iliac crest, while the hip circumference measurement was taken at the
point of greatest protuberance of the participant's buttocks when
viewed from the side. The ratio of waist to hip circumference was
calculated by dividing waist circumference by hip circumference. A 3-T
MRI scanner (Discovery MR750; GE Healthcare) was used to assess
abdominal fat volume (subcutaneous and visceral adipose tissue from
the diaphragm to the pelvis, with a slice thickness of 10 mm and an
interslice gap of 10 mm). Accelerometers (SenseWear Pro Armband;
BodyMedia Inc) were used to assess physical activity [26]. Physical
activity data was included as a covariate in our analyses if participants
wore the accelerometer for a minimum of 5 of 7 designated days for at
least 85% of each 24-hour day. Mean physical activity across the days
the accelerometer was worn was then entered into analyses as meta-
bolic equivalents of task (equal to total energy expenditure divided by
resting energy expenditure; calculated by SenseWear Professional
Software version 7.0 [BodyMedia Inc]).101 Random
46 Completed 12-month severe intervention
50 Randomized to the severe intervention
45 Completed 24-month time point
1 Discontinued the trial
1 Health reasonsunrelated to trial
41 Completed 36-month time point
4 Discontinued the trial
1 No longer able to commit
1 Hair loss/Alopecia   
1 Lost to follow-up
1 Dissatisfied with diet   
Figure 1. Flow of participants through the TEMPO Diet Trial (Type of Energy Ma
Obesity). The moderate intervention involved a food-based diet with a 25 to 35% e
involved total diet replacement with 65 to 75% energy restriction for 4 months (16 w
height in meters squared) of no lower than 20 kg/m2 was reached, whichever cam
Participants were then followed up at 24 and 36 months. Reasons for discontinuing
outcomes to 12 months [9].
32.4. Statistical analysis
Statistical analyses were performed using SPSS statistical software
version 24 for Windows (IBM Corp). Statistical significance was accepted
as P < 0.05. Fisher exact tests were used to compare attrition between
groups (ie, severe versus moderate). All continuous variables were
assessed for normality before analysis using histograms and P–P plots. To
compare continuous variables between groups at baseline (0 months),
Mann-Whitney tests were used.
To compare longitudinal changes between groups, intention-to-treat
analysis was performed using all available follow-up data from all par-
ticipants originally randomized, using random-effects linear mixed
models. While data from all time points was used in these models, this
article reports on the differences between groups at 24 and 36 months,
and the differences within each group between 24 or 36 months and
baseline, because the data to 12 months has previously been published
[9]. Intervention group and time were included as fixed effects, and
participant was included as a random effect. For all outcomes, baseline
values of the relevant variable were added as a covariate in the analysis.
As the degree of physical activity is known to influence measures of bodyized
39 Completed 12-month moderate intervention
51 Randomized to the moderate intervention
7 Discontinued the trial
4 No longer able to commit
2 Lost to follow-up
1 Health reasonsunrelated to trial 
1Could not attend testing at the 24-month time
point but attended the 36-month time point 
31 Completed 24-month time point
1 Discontinued the trial
1 No longer able to commit
31 Completed 36-month time point
nipulation for Promoting optimum metabolic health and body composition in
nergy restriction for a total of 12 months (52 weeks). The severe intervention
eeks) or until a body mass index (calculated as weight in kilograms divided by
e first, followed by moderate energy restriction until 12 months (52 weeks).
the trial between 0 and 12 months have been published previously, along with
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task) was added as a covariate, as measured at each time point. When the
overall P value for the interaction between group and time was less than
0.05, comparisons between groups at each of the 2 time points relevant to
this paper (ie, at 24 and 36 months) were made, using Bonferroni ad-
justments to correct for multiple comparisons. For within-group changes,
intervention group and time were included in the model as fixed effects
and time as a repeated measure, with physical activity (metabolic
equivalents of task) added as a covariate. Maximum-likelihood estima-
tion was used, and an unstructured covariance matrix was specified.
Comparisons between time points (ie, 24 or 36 months) and baseline (0
months) within each group were made using Bonferroni adjustments to
correct for multiple comparisons.
3. Results
Participants were recruited between March 2013 and July 2016,
and 101 participants were randomized to the trial (Figure 1). Partici-
pants had a mean (SD) age of 58.0 (4.2) years, a mean (SD) weight of
90.8 (9.1) kg, and a mean (SD) body mass index of 34.4 (2.5) kg/m2 at
baseline (0 months, Table 1). There were no differences between
groups at baseline in any of these variables or race (severe: 47 of 50
[94.0%] white participants; moderate: 48 of 51 [94.1%] white par-
ticipants), or outcome variables (Table 1). Overall, 76 of 101 (75.2%)Table 1. Baseline characteristics for all participants, completers and noncompleters,
Characteristic
Severe Group
All participants (n ¼ 50) Completers (n ¼ 41) Noncom
Age, y 58.0 (4.4) 58.2 (4.4) 57.1 (4.4
Height, m 1.62 (0.06) 1.62 (0.06) 1.61 (0.0
Weight, kg 90.1 (9.4) 89.2 (8.9) 94.5 (11
Body mass index, kg/m2a 34.3 (2.5) 33.9 (2.4) 36.2 (1.8
Lean tissues
Whole-body lean mass, kgb 44.3 (4.9) 44.0 (4.5) 45.5 (6.6
Muscle strength, kg
Dominant handc 29.80 (6.31) 29.25 (6.20) 32.22 (6
Non-dominant hand 27.90 (6.00) 27.17 (5.51) 31.22 (7
Bone mineral density, g/cm2
Total hipd 0.988 (0.097) 0.979 (0.091) 1.028 (0
Femoral neckd 0.810 (0.089) 0.800 (0.080) 0.853 (0
Lumbar spine 1.001 (0.112) 0.991 (0.114) 1.045 (0
Whole-bodyb 1.093 (0.077) 1.093 (0.079) 1.091 (0
Fat mass and distribution
Waist circumference, cm 108.3 (7.3) 108.0 (7.5) 109.8 (6
Hip circumference, cm 118.6 (7.0) 117.6 (6.6) 123.4 (7
Ratio of waist to hip circumferencee 0.915 (0.061) 0.920 (0.061) 0.891 (0
Whole-body fat mass, kgb 42.2 (5.6) 41.5 (5.5) 45.5 (5.2
Abdominal adipose tissue, cm3
Subcutaneousf,g 12006 (3028) 11767 (3088) 13175 (
Visceralf 4544 (1702) 4549 (1734) 4526 (16
Abbreviation: TEMPO, Type of Energy Manipulation for Promoting optimum metabo
Data are presented as means (standard deviations).
a Calculated as weight in kilograms divided by height in meters squared.
b Data for 2 participants in the moderate group who completed the study are missi
c Data for 1 participant in the severe group who completed the study are missing bec
in the moderate group who completed the study are missing because the participant
d Data for 1 participant in the moderate group who completed the study are missin
e Calculated as waist circumference divided by hip circumference.
f Data for 2 participants in the severe group who completed the study and 1 in the m
undergo magnetic resonance imaging scan.
g Data for 1 participant in the severe group who did not complete the study and 3
because the scan was outside the window of analysis.
4and 72 of 101 (71.3%) of participants completed the 24-month and 36-
month time points respectively (45 of 50 [90.0%] in the severe group
versus 31 of 51 [60.8%] in the moderate group at 24 months, and 41 of
50 [82.0%] in the severe group versus 31 of 51 [60.8%] in the mod-
erate group at 36 months). There were 3.5-fold fewer participants
discontinuing the trial in the severe group compared with the moderate
group at 24 months (6 versus 21 participants; P ¼ 0.0001), and 2.2-fold
fewer discontinuations at 36 months (9 versus 20 participants; P ¼
0.05) (Figure 1).3.1. Weight
The severe group had a significantly lower weight than the moderate
group at both 24 and 36 months (effect size at 36 months, 2.9 [95% CI,
5.0 to0.8] kg; estimatedmarginal means at 36months,8.0 [95% CI,
11.7 to 4.4] kg versus 4.9 [95% CI, 8.9 to 0.9] kg; P ¼ 0.008)
(Figure 2A and Table 2). Both groups had significant decreases in weight
at 24 and 36 months compared with baseline, although there was weight
regain between 12 to 36 months in participants in both the severe group
(effect size 7.3 [95% CI, 4.5 to 10.2] kg, P < 0.001) and the moderate
group (effect size 3.2 [95% CI, -0.1 to 6.4] kg, P ¼ 0.065). At 24 months,
27 of 45 participants (60.0%) in the severe group who remained in the
trial had lost at least 10% of their baseline weight compared with 9 of 31
participants (29.0%) in the moderate group who remained in the trial (Pin the TEMPO Diet Trial.
Moderate Group
pleters (n ¼ 9) All participants (n ¼ 51) Completers (n ¼ 31) Noncompleters (n ¼ 20)
) 58.0 (4.2) 57.7 (4.2) 58.3 (4.2)
8) 1.63 (0.05) 1.63 (0.06) 1.63 (0.04)
.1) 92.4 (8.3) 93.3 (9.0) 91.0 (6.9)
) 34.6 (2.5) 35.0 (2.7) 34.1 (2.2)
) 44.8 (4.0) 45.0 (4.4) 44.6 (3.3)
.55) 30.00 (4.70) 30.37 (4.79) 29.45 (4.64)
.34) 27.90 (4.42) 28.48 (4.82) 27.00 (3.64)
.117) 0.972 (0.107) 0.971 (0.105) 0.974 (0.114)
.118) 0.815 (0.097) 0.818 (0.090) 0.810 (0.110)
.097) 1.019 (0.125) 0.995 (0.124) 1.057 (0.120)
.069) 1.100 (0.088) 1.087 (0.082) 1.118 (0.094)
.5) 108.8 (7.0) 109.7 (8.2) 107.4 (4.3)
.2) 121.3 (6.6) 122.2 (6.1) 119.9 (7.2)
.057) 0.898 (0.060) 0.899 (0.065) 0.898 (0.053)
) 43.5 (5.9) 44.2 (6.2) 42.5 (5.4)
2567) 12176 (2508) 12174 (2540) 12181 (2527)
54) 5123 (1954) 5168 (1976) 5049 (1969)
lic health and body composition in Obesity.
ng because of machine failure.
ause the participant underwent thumb tendon surgery, and data for 1 participant
had a scaphoid fracture.
g because the scan could not be analyzed.
oderate group who did not complete the study are missing because they did not
participants in the moderate group (2 completers, 1 noncompleter) are missing
Figure 2. Weight changes in postmenopausal women with obesity during the
TEMPO Diet Trial (Type of Energy Manipulation for Promoting optimum
metabolic health and body composition in Obesity). Weight data presented as
estimated marginal means (A), ie, group means after controlling for covariates.
Whiskers (mostly obscured by the data points) indicate SEs of the means. Weight
change at 24 (B) and 36 months (C) as percentage change from baseline for each
participant in the severe and moderate groups. The dotted lines indicate 10%
weight loss. a P < 0.001 versus baseline value within group. b P < 0.01 versus
the moderate group at that time point. Statistical comparisons between groups
in the first 12 months of the trial have been published previously [9].
R.V. Seimon et al. Heliyon 6 (2020) e04007< 0.001) (Figure 2B). Assuming participants who dropped out of the trial
did not achieve at least 10% weight loss, then 27 of 50 participants
(54.0%) in the severe group had lost at least 10% of their baseline weight
compared with 9 of 51 participants (17.6%) in the moderate group (P <
0.001) at 24 months. This represents a 3.1-fold greater likelihood of
losing a clinically significant amount of weight (ie, 10%) with the severe
versus moderate intervention at 24 months. At 36 months, 21 of 41
participants (51.2%) in the severe group who remained in the trial had
lost at least 10% of their baseline weight compared with 8 of 31 partic-
ipants (25.8%) in the moderate group who remained in the trial (P <
0.01) (Figure 2C). Assuming participants who dropped out of the trial did
not achieve at least 10% weight loss, then 21 of 50 participants (42.0%)5in the severe group had lost at least 10% of their baseline weight
compared with 8 of 51 participants (15.7%) in the moderate group (P <
0.01) at 36 months. This represents an approximately 2.6-fold (42%
versus 16%) greater likelihood of losing a clinically significant amount of
weight (ie, 10%) with the severe versus moderate intervention at 36
months.
3.2. Lean tissues
The severe group had significantly lower values of whole-body lean
mass compared with the moderate group at both 24 and 36 months
(effect size at 36 months, 1.7 [95% CI, 3.4 to 0.1] kg; estimated
marginal means at 36 months, 2.8 [95% CI, 3.9 to 1.6] kg versus
2.0 [95% CI, 3.2 to 0.7] kg; P ¼ 0.004) (Figure 3A and Table 2).
After adjusting for body weight at each time point, there was no signif-
icant difference in whole-body lean mass between the severe and mod-
erate group at 24 or 36 months. Both groups had significant decreases in
whole-body lean mass at 24 and 36 months compared with baseline,
although whole-body lean mass remained unchanged between 12 and 36
months in participants in both the moderate (0.20 [-0.81 to 1.21] kg, P¼
1.00) and severe groups (0.55 [-0.35 to 1.44] kg, P ¼ 1.00).
Apart from a significantly greater handgrip strength in the dominant
hand of the severe compared to the moderate group at 36 months, there
was no difference between groups in handgrip strength of the dominant
or nondominant hand at 24 or 36 months (effect size at 36 months for the
dominant and non-dominant hands: 1.89 [95% CI, 0.22 to 3.56] kg and
0.08 [95% CI, 1.51 to 1.68] kg, respectively; estimated marginal
mean at 36 months for the dominant hand: 2.25 [95% CI, 4.02 to
-0.47] kg versus 4.20 [95% CI, 6.12 to -2.28]; nondominant hand:
2.80 [95% CI, 4.68 to -0.91] kg versus 2.81 [95% CI, 4.84 to
-0.77] kg) (Figure 3B and Table 2). Both groups had significant decreases
in dominant and nondominant handgrip strength at 24 and 36 months
compared with baseline.
3.3. Bone mineral density
The severe group had significantly lower total hip BMD than the
moderate group at both 24 and 36 months (effect size at 36 months,
0.016 [95% CI, 0.029 to -0.002] g/cm2; estimated marginal means
at 36 months, 0.038 [95% CI, 0.054 to 0.021] g/cm2 versus
0.019 [95% CI, 0.038 to 0.001] g/cm2; P < 0.05) (Figure 3C and
Table 2). After adjusting for body weight at each time point, there was
still a significant difference in total hip BMD between the severe and
moderate group at 24 (P < 0.01), but not at 36 months (P ¼ 0.09). The
severe group had significantly lower femoral neck (Table 2) and whole-
body BMD (Figure 3D) than the moderate group at 36 but not at 24
months, but there were no significant differences between groups in
lumbar spine BMD (Table 2). The severe group had significant de-
creases from baseline in total hip, femoral neck and lumbar spine (but
not whole-body) BMD at both 24 and 36 months, while the moderate
group had significant decreases from baseline in total hip BMD at 36
but not at 24 months, and significant decreases from baseline in
femoral neck and lumbar spine (but not whole-body) BMD at both 24
and 36 months (Figures 3C and 3D, Table 2). Further, there was no
change in total hip BMD between 12 and 36 months in either the se-
vere (-0.004 [95% CI, -0.019 to 0.010] g/cm2; P ¼ 1.00) or moderate
group (-0.004 [95% CI, -0.021 to 0.013], g/cm2; P ¼ 1.00).
There was no difference in the number of participants with osteo-
penia (defined as a T-score between -1 and -2.5) [27] at the femoral
neck between groups at 36 months, although there was a significant
increase from baseline in the number of participants with osteopenia at
the femoral neck in both the severe and moderate group (severe:
0 months, 8/50 [16.0%]; 36 months, 25/41 [60.9%]; P < 0.001;
moderate: 0 months, 12/50 [24.0%]; 36 months, 17/30 [56.6%]; P <
0.01). In the total hip, there was also no difference between the severe
or moderate groups in the number of participants with osteopenia at 36
Table 2. Changes from baseline for body composition with the severe and moderate energy restriction interventions of the TEMPO Diet Trial.
Measurement No. Severe Group,
Estimated Marginal Mean
(95% CI)
No. Moderate Group,
Estimated Marginal Mean
(95% CI)
P Valuea
Weight change, kg
24 mo 45 -10.0 (-13.3 to -6.6)b 31 -6.0 (-9.7 to -2.4)b <0.001
36 mo 41 -8.0 (-11.7 to -4.4)b 31 -4.9 (-8.9 to -0.9)b 0.008
Weight change, % of baseline
24 mo 45 -11.2 (-14.9 to -7.6)b 31 -6.7 (-10.7 to -2.7)b <0.001
36 mo 41 -9.0 (-12.9 to -5.1)b 31 -5.5 (-9.8 to -1.2)f 0.012
Body mass index change, kg/m2c
24 mo 45 -3.79 (-5.08 to -2.49)b 31 -2.25 (-3.67 to -0.84)b 0.001
36 mo 41 -2.94 (-4.37 to -1.51)b 31 -1.61 (-3.17 to -0.04)e 0.007
Lean tissues
Whole-body lean mass change, kgd
24 mo 45 -2.9 (-3.9 to -1.9)b 31 -1.9 (-3.1 to -0.8)b 0.02
36 mo 41 -2.8 (-3.9 to -1.6)b 31 -2.0 (-3.2 to -0.7)b 0.04
Muscle strength change, kg
Dominant hand
24 mo 44 -1.91 (-3.70 to -0.13)e 31 -3.21 (-5.24 to -1.18)b 0.16
36 mo 41 -2.25 (-4.02 to -0.47)f 31 -4.20 (-6.12 to -2.28)b 0.03
Non-dominant hand
24 mo 45 -2.33 (-4.09 to -0.58)f 31 -3.07 (-5.04 to -1.11)b 0.30
36 mo 41 -2.80 (-4.68 to -0.91)b 31 -2.81 (-4.84 to -0.77)f 0.92
Bone mineral density, g/cm2d
Total hip change
24 mo 45 -0.030 (-0.046 to -0.015)b 30 -0.007 (-0.025 to 0.011) <0.001
36 mo 41 -0.038 (-0.054 to -0.021)b 30 -0.019 (-0.038 to -0.001)e 0.02
Femoral neck change
24 mo 45 -0.046 (-0.067 to -0.025)b 30 -0.039 (-0.063 to 0.015)b 0.36
36 mo 41 -0.063 (-0.085 to -0.040)b 30 -0.045 (-0.070 to -0.020)b 0.047
Lumbar spine change
24 mo 45 -0.046 (-0.065 to -0.028)b 31 -0.042 (-0.063 to -0.021)b 0.31
36 mo 41 -0.044 (-0.065 to -0.022)b 31 -0.048 (-0.073 to -0.024)b 0.77
Whole-body change
24 mo 45 -0.015 (-0.041 to 0.011) 31 -0.005 (-0.035 to 0.026) 0.06
36 mo 41 -0.021 (-0.051 to 0.008) 31 0.002 (-0.031 to 0.036) 0.007
Fat mass and distribution
Waist circumference change, cm
24 mo 45 -9.4 (-12.7 to -6.2)b 31 -5.1 (-8.8 to -1.5)f <0.001
36 mo 41 -7.4 (-10.8 to -3.9)b 31 -4.3 (-8.1 to -0.4)e 0.04
Hip circumference change, cm
24 mo 45 -6.6 (-9.1 to -4.2)b 31 -4.7 (-7.4 to -1.9)b 0.005
36 mo 41 -5.9 (-8.5 to -3.2)b 31 -4.4 (-7.3 to -1.5)b 0.046
Ratio of waist to hip circumference changeg
24 mo 45 -0.020 (-0.062 to 0.022) 31 0.003 (-0.043 to 0.050) 0.02
36 mo 41 -0.030 (-0.075 to 0.014) 31 0.006 (-0.042 to 0.054) 0.005
Whole-body fat mass change, kgd
24 mo 45 -5.9 (-8.1 to -3.7)b 31 -3.3 (-5.8 to -0.9)f <0.001
36 mo 41 -4.8 (-6.9 to -2.6)b 31 -3.1 (-5.6 to -0.7)f 0.001
Abdominal adipose tissue change, cm3
Subcutaneous
24 mo 40 -2341 (-3161 to -1520)b 29 -1551 (-2454 to -647)b 0.01
36 mo 35 -1986 (-2900 to -1072)b 26 -1477 (-2504 to -451)f 0.16
Visceral
24 mo 40 -1647 (-2199 to -1094)b 30 -999 (-1594 to -403)b 0.001
36 mo 35 -1287 (-1868 to -705)b 26 -866 (-1502 to -229)f 0.03
Abbreviations: CI, confidence interval; mo, months; TEMPO, Type of Energy Manipulation for Promoting optimum metabolic health and body composition in Obesity.
Bolded P values in the right-hand column represent P values that are less than 0.05.
a P values for comparison between the severe and moderate interventions at each time point.
b P < 0.001 versus baseline for that group. For within-group comparisons between follow-up and baseline values, a repeated-measures linear mixed model was used.
R.V. Seimon et al. Heliyon 6 (2020) e04007
6
c Calculated as weight in kilograms divided by height in meters squared.
d Measured by dual-energy x-ray absorptiometry.
e P < 0.05 versus baseline for that group. For within-group comparisons between follow-up and baseline values, a repeated-measures linear mixed model was used.
f P < 0.01 versus baseline for that group. For within-group comparisons between follow-up and baseline values, a repeated-measures linear mixed model was used.
g Calculated as waist circumference divided by hip circumference.
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baseline to 36 months in either group (severe: 0 months, 0/50; 36
months, 3/41 [7.3%]; moderate: 0 months, 3/50 [6.0%]; 36 months,
3/30 [10.0%]). There were no participants with osteoporosis of the hip
(defined as a T-score of -2.5 or less) [27] at 0 or 36 months in the severe
or moderate group.3.4. Fat mass and distribution
The severe group had significantly lower waist and hip circumfer-
ences, and significantly lower values of waist to hip ratio compared with
the moderate group at both 24 and 36 months (effect size for waist
circumference at 36 months, 2.4 [95% CI, -4.7 to -0.1] cm; estimated
marginal means of waist circumference at 36 months, 7.4 [95% CI,
10.8 to 3.9] cm versus 4.3 [95% CI, 8.1 to 0.4] cm; P < 0.05;
effect size for hip circumference at 36 months, 1.88 [95% CI, 0.05 to
-0.03] cm; estimated marginal means of hip circumference at 36 months,
5.9 [95% CI,8.5 to3.2] cm versus4.4 [95% CI,7.3 to1.5] cm;
P < 0.05) (Figure 3E, Table 2). Both groups had significant decreases
from baseline in waist and hip circumference (but not in the ratio of waist
to hip circumference) at 24 and 36 months. Compared with the moderate
group, the severe group had significantly lower whole-body fat mass at
both 24 and 36 months (effect size at 36 months, 5.5 [95% CI, 7.1 to
3.9] kg; estimated marginal means at 36 months, 10.2 [95% CI,
12.1 to 8.4] kg versus 5.5 [95% CI, 7.5 to 3.4] kg; P < 0.001)
(Figure 3F and Table 2). The severe group also had significantly lower
values for abdominal subcutaneous adipose tissue volumes than the
moderate group at 24, but not at 36 months (effect size at 36 months,
561 [95% CI, 1352 to -229] cm3; estimated marginal means at 36
months, 1986 [95% CI, 2900 to 1072] cm3 versus 1477 [95% CI,
2504 to 451] cm3; P ¼ 0.16) (Figure 3G and Table 2), and signifi-
cantly lower values for abdominal visceral adipose tissue volume at both
24 and 36 months (effect size at 36 months, 521 [95% CI, 978 to -65]
cm3; estimated marginal means at 36 months, 1287 [95% CI, 1868 to
705] cm3 versus 866 [95% CI, 1502 to 229] cm3; P < 0.05)
(Figure 3H and Table 2). Both groups had significant decreases from
baseline at 24 and 36 months in whole-body fat mass, abdominal sub-
cutaneous adipose tissue and abdominal visceral adipose tissue
(Figures 3F, 3G and 3H, Table 2). In the severe group, between 12 to 36
months, there was an increase in whole-body fat mass (effect size 5.5
[95% CI, 3.5 to 7.6] kg, P < 0.001), subcutaneous (effect size 1421 [95%
CI, 563 to 2280] cm3, P < 0.001) and visceral (effect size 1135 [95% CI,
689 to 1580] cm3, P< 0.001) abdominal adipose tissue volumes, while in
the moderate group between 12 to 36 months there was a trend for an
increase in whole-body fat mass (effect size 2.2 [95% CI, -0.1 to 4.5] kg, P
¼ 0.065), but no change in subcutaneous (effect size 163 [95% CI, -795
to 1121] cm3, P¼ 1.00) or visceral (effect size 202 [95%CI, -299 to 702])
cm3, P ¼ 1.00) abdominal adipose tissue volumes.3.5. Adverse events
There were 8 adverse events reported in 8 participants between 12
and 36 months, all in the severe group. Of these 8 adverse events, 5 were
related or possibly related to the intervention, and 3 were not related to
the intervention. The adverse events were gallstones (2 participants,
which represents 4.0% of participants [2 of 50] in the severe interven-
tion), breast cancer (2 participants [4.0%]), hemorrhoids (1 participant
[2.0%]), hair loss/alopecia (1 participant [2.0%]), type 2 diabetes (17participant [2.0%]), and osteoporosis of the spine (1 participant [2.0%],
who had seen a specialist whomade the diagnosis). We had also observed
osteoporosis of the spine in this participant in our DXA scans at 24 and 36
months, where her T-score for the spine was -2.5 and -2.6, respectively.
However, as her T-score for the hip was greater than the threshold for
osteoporosis (-2.5 or less) [27], and as we had decided a priori to assess
osteoporosis based on the hip rather than the spine due to measurement
artifacts being common in the spine, we did not classify this participant
as having osteoporosis.
4. Discussion
This 3-year follow up on a randomized clinical trial showed that
postmenopausal women with obesity who had undergone severe energy
restriction lost approximately 1.5 to 1.7 times as much net weight, waist
circumference, whole-body fat mass and visceral adipose tissue
compared to those who had undergone moderate energy restriction, and
were 2.6 times more likely (42% versus 16%) to have lost 10% or more of
their initial body weight at 3 years. However, those in the severe versus
moderate intervention lost approximately 1.4 times as much whole-body
lean mass (albeit this was proportional to total weight lost and there was
no greater loss of handgrip strength), and approximately 2 times as much
total hip bone mineral density between 0 and 3 years, with this bone loss
occurring in the first year.
As with all weight loss trials, we observed weight regain in partici-
pants in both the severe and moderate groups by 36 months. Interest-
ingly, the only participants who gainedmore than 5% of their initial body
weight were from the severe group, with 3/50 of these participants
(6.0%) regaining 11 to 14% of their initial body weight at 36 months.
Such weight gain was not seen in any individuals in the moderate group.
Although there is insufficient data to say if this difference is statistically
significant, it is important to be aware that some individuals may need
close monitoring following a severely energy-restricted diet, such as the
total meal replacement diet used in this trial, and if rapid weight regain is
evident then more intensive strategies to assist with weight maintenance
could be deployed.
In terms of composition, it appears that weight regains in both the
severe and moderate groups between 12 to 36 months were largely due
to increases in fat mass, with whole-body lean mass remaining largely
unchanged during this time. These results are in line with other studies
suggesting that fat mass is regained to a greater degree than lean mass in
postmenopausal women after weight loss [28]. In our study, muscle
strength did not decrease from baseline during the 12-month interven-
tion (although it did decrease between 12 and 36 months), which sug-
gests that muscle quality was maintained during the intervention despite
an apparent loss of muscle quantity (as indicated by reduced whole-body
lean mass). This is important because muscle quality has been shown to
be a more important predictor of health risk than muscle quantity [29,
30, 31]. The overall decrease in handgrip strength seen in both groups
between 12 and 36 months (approximately 2 to 4 kg) was on par with the
approximately 6 kg decrease in handgrip strength observed in women in
the 2 decades of life between the ages of 45 and 65 years [32].
Despite weight and fat regain between 12 and 36 months in partici-
pants in both interventions, at 36 months those in the severe intervention
still weighed significantly less and had significantly lower waist and hip
circumference, waist to hip ratio, whole-body fat mass and visceral
abdominal adipose tissue volume than those in the moderate interven-
tion. This finding counters the theory that the fast weight loss associated
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especially abdominal fat regain [17]. Therefore, severe energy restriction
(with a meal replacement diet) is more effective than moderate energy
restriction (with a food-based diet) in terms of reducing body weight and
fat – including the more pathogenic visceral adipose tissue – in the long
term (3 years), at least in postmenopausal women with obesity.Figure 3. Effect of severe versus moderate energy restriction on body composition
means after controlling for covariates) of lean tissues: whole-body lean mass (A), musc
body (D); and fat mass and distribution: waist circumference (E), whole-body fat mass
tissue (H) in the severe and moderate groups during the 36 months of the TEMPO
Whiskers indicate SEs of the means. Abbreviation: BMD, bone mineral density. a P < 0
that time point. Statistical comparisons between groups in the first 12 months of th
8The greater long-term weight and fat loss during severe versus
moderate energy restriction must be considered in light of a greater loss
of BMD. In this trial, participants in the moderate group exhibited an
approximately 1.9% reduction in total hip BMD over the 36-month trial.
This was under what was expected within 3 years, considering that the
annual rate of BMD loss at the hip in the early postmenopausal years isin postmenopausal women with obesity. Estimated marginal means (ie, group
le strength of the dominant hand (B); bone mineral density: total hip (C), whole-
(F), abdominal subcutaneous adipose tissue (G), and abdominal visceral adipose
Diet Trial. Baseline values were the covariates in the statistical analysis model.
.05 versus baseline value within group. b P < 0.05 versus the moderate group at
e trial have been published previously [9].
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participants in the severe group exhibited an approximately 3.7%
reduction in total hip BMD over the 36months, which was still within the
expected loss of BMD over 3 years based on the annual rate of BMD loss at
the hip in this population, but total hip BMD loss at 36 months was still 2
times higher in the severe than the moderate group. Interestingly, there
was no change in total hip BMD between 12 and 36 months in either the
moderate or severe groups, despite weight regain during this period. It
appears that total hip BMD loss only occurs in the first 12 months of a
weight loss intervention, after which time it remains low and is not
regained, even if weight is regained. These findings are consistent with
other research suggesting that BMD loss during weight reduction may not
be fully recovered with weight regain in postmenopausal women [34,
35].
Although weight variability has been shown to increase the risk of hip
fractures in adults [36], the long-term impact of energy restriction on
fractures is not clear, particularly when it is used for intentional weight
loss [37, 38]. For instance, a study of 120,566 postmenopausal women
(50 to 79 years of age at baseline) showed that those who unintentionally
lost 5% or more of their body weight over 3 years – compared to those
who remained weight stable – had 33% higher incidence rates of hip
fracture and 16% higher incidence rates of vertebral fracture, while those
who intentionally lost 5% or more of their body weight had 15% lower
incidence rates of hip fracture and 11% higher incidence rates of lower
limb fracture [39]. It is possible that one bout on a severely
energy-restricted diet may not induce an increase in osteoporotic fracture
risk, but the effects of repeated bouts of a severely energy-restricted diet,
done over many years as a way of maintaining a lower weight [40], is not
known.
In light of the effect of severe energy restriction to reduce BMD more
than moderate energy restriction, at least in postmenopausal women
with obesity, as well as the currently unknown impact of diet-induced
BMD loss on long-term fracture risk, it could be important to monitor
BMD in people who undertake severely energy-restricted diets for weight
management. It would also seem prudent to recommend strategies to
protect bone health during adherence to a severely energy-restricted diet.
One such strategy would be to ensure adequate dietary intake of calcium
and vitamin D during the diet. While it is unlikely that dietary de-
ficiencies in these micronutrients could explain the greater BMD loss
observed in the severe versus moderate intervention, because the meal
replacement products used here met the estimated needs for calcium and
vitamin D for women of the ages recruited for this trial (45 to 65 years)
[53], dietary deficiencies could potentially worsen bone loss during a
severely energy-restricted total meal replacement diet. Of note, while the
currently-used brand of total meal replacement product met the pre-
vailing Australian recommended dietary intake for calcium for women
aged 19 to 70 years, 2 of the 7 other brands available on the local market
did not [53]. Moreover, for people aged over 70 years, none of the 8
locally-available brands – including the brand used in this trial – met the
recommended dietary intake of calcium [53]. For Vitamin D, only 3 of
the 8 locally-available brands of total meal replacement products –
including the brand used in this trial – provided adequate intake for
adults aged 51 years and over [53]. Therefore, it would be important to
check the nutritional content of the total meal replacement brand to be
used, and consider whether another brand may be more suitable, or
whether supplementation with calcium and vitamin D may be required.
Another strategy to protect bone health during adherence to a severely
energy-restricted diet could be to strongly recommend muscle strength-
ening exercises. Although it is not clear that strength training would have
prevented the greater BMD loss in the severe versus the moderate
intervention in participants in the current trial, as is the case for other
trials that administered either moderate [41, 42, 43, 44] or severe [45]
energy restriction, there is strong evidence that strength training at least
twice per week has numerous health benefits for men and women of all
ages [46, 47, 48]. As such, there seems little harm in recommending9regular muscle strengthening exercises during a severely
energy-restricted diet, subject to approval from the healthcare
professional.
Over the course of this trial, ie, between baseline and 36 months, the
two most common intervention-related (or possibly intervention-related)
side-effects noted were haemorrhoids and gallstones. Haemorrhoids
were noted by 3 of the 50 participants (ie, 6.0%) that underwent the
severely energy-restricted diet. Two participants (4.0%) reported hae-
morrhoids during the first 12 months, reported in our publication of
outcomes to 12 months [9], and 1 (2.0%) reported haemorrhoids be-
tween 12 and 36 months, which is not likely due to the intervention.
Further, 4 of the 50 participants (8.0%) in the severe group reported
gallstones over the course of the trial. Therefore, people undergoing
severely energy-restricted diets could benefit from being informed about
these side-effects so that strategies to prevent or remedy them can be
taken. For example, after these 2 cases of haemorrhoids were reported
within the first 12 months, we started giving participants a 1-page in-
formation sheet about avoiding and managing constipation by being
aware of bowel movements, eating the prescribed 2 cups of non-starchy
vegetables every day (which provide approximately 3 g of additional
dietary fibre), drinking at least 2 L of water every day, being physically
active, and taking laxatives (eg, fibre supplements) if necessary (Sup-
plement 1). We also reiterated the importance of these instructions every
2 weeks while participants were on the diet, and provided samples of
suitable laxatives to help allay constipation when indicated, such that no
further cases of haemorrhoids were reported during the intervention.
These instructions are particularly important given that none of the 8
locally-available brands of total meal replacement products provided
more than 12.4 g of dietary fibre per day (assuming use of 3 products per
day) [53], which is less than half the adequate intake of fibre for adults of
all ages (25 g per day for women and 30 g per day for men in Australia)
[49]. Further to recommending strategies to prevent constipation, it may
be important for healthcare professionals to monitor for any signs of
gallstones during and after a severely energy-restricted diet so that
suitable actions can be taken if required.4.1. Strengths and limitations
Strengths of this study include the randomized clinical trial design,
with long-term follow-up at 24 and 36 months, as well as the fact that
data variability was reduced by analysis of all data by a single researcher
(ie, S.M. for DXA and A.L.W.-T. for MRI). A limitation of our trial is that
participants were predominantly white, which limits the generalizability
of the findings to populations of other races. An additional limitation is
that changes in BMD observed using DXA during large weight losses
might be exaggerated because of the varying amounts of soft tissue sur-
rounding bone over time, which can result in unpredictable errors of up
to 20% in BMD measurements [50, 51]. However, DXA remains the gold
standard and the only available test for measuring BMD in clinical
practice [52].
5. Conclusions
Severe energy restriction is more effective than moderate energy re-
striction for reducing weight and adiposity in the long term (3 years), but
attention to bone mineral density loss in the first year is required in
postmenopausal women.
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